The immune checkpoint protein B7‑H4 plays an important role in the positive as well as the negative regulation of immune T‑cell responses. When expressed on cancer cells, B7‑H4 inhibits T‑cell activity, and numerous types of cancer cells use upregulation of B7‑H4 as a survival strategy. Thus, B7‑H4 is a potential target for anticancer drug therapy.
View Article and Find Full Text PDFBackground: Systemic treatment options for generalized atopic dermatitis (AD) are limited. To our knowledge, there have been no prospective trials examining the use of oral tacrolimus, a calcineurin inhibitor, in AD.
Objectives: We assessed the safety and efficacy of sequential therapy with oral tacrolimus and topical tacrolimus in the treatment of generalized AD using the Eczema Area and Severity Index and the Physician Global Assessment scores as the primary end points.